The Indigo Study
Currently Recruiting
16 Sep 2026
Up to $4,200
Brisbane, Australia
This study is looking at an investigational oral drug for people living with obesity or overweight.
Obesity is a chronic disease that is estimated to affect ~880 million adults globally. Adults living with obesity and overweight are at higher risk for other health problems. For some people, medicines are recommended to support weight management; however, more treatment options are needed to treat this chronic disease. The investigational drug is an oral tablet that is designed to help people feel full sooner and reduce feelings of hunger, which may help people eat less over time.
Join our clinical trial
This is a first-in-human (FIH) study, meaning it is the first time the investigational medicine is being tested in people. The study has been carefully designed with strict safety protocols and has been reviewed by an independent ethics committee. It is not known whether the investigational medicine may cause unexpected, serious, or life-threatening side effects. While these are considered unlikely, you will be carefully monitored throughout the study and provided with prompt treatment if any such effects occur.
Before joining, you’ll receive detailed information about the study, meet with a doctor, and have the chance to ask any questions.
What to expect
- Participation in a monitored clinical environment
- Support from a professional medical team
- Compensation for your time and commitment will be provided to participants who complete the full study
Study schedule
| Intake 1 | In-clinic stay:
16 September 2026 –20 September 2o26 |
Follow-up visits:
23 September 2026 – 16 October 2026 |
| Intake 2 | In-clinic stay:
30 September 2026 –4 October 2o26 |
Follow-up visits:
7 October 2026 –30 October 2026 |
Study dates are subject to change. Our team will confirm details with you during the screening process.
Trial details
Study duration
- 4 night inpatient stay
- 5 follow-up visits
Study medication
The study drug or placebo will be given as an oral tablet
Additional eligibility
- Stable body weight (≤5% change within 3 months)
- Non-smoker, or smoking 10 or less cigarettes (or equivalent) per day, and agrees to abstain for the duration of the study
- Not pregnant or breastfeeding
- Willing to follow contraception guidelines (If applicable)
- Willing and able to attend all study visits and follow instructions
- Other eligibility criteria apply
Ethics
An independent ethics committee has approved this clinical trial.
Are you a match?
Age
18 - 60 years old
Remuneration
Up to $4,200 *with screening reimbursement.
Full details outlined in consent form.
Gender
Male, Female, Female (Post-menopausal) or Female of non-childbearing potential
BMI
BMI 25 - 35 kg/m2
Commitment
4 nights, 5 clinic visits
Medical condition
Not taking any medications